COVID-19 and Influenza Vaccine Combo Study Launches
Maryland-based Novavax, Inc. announced enrollment of the first participants in a Phase 1/2 study conducted in Australia to evaluate the safety and immunogenicity of a combination vaccine using its seasonal influenza and COVID-19 vaccine candidates, with results expected during the first half of 2022.
The clinical trial combines Novavax's recombinant protein-based NVX-CoV2373 and NanoFlu™ vaccines and patented saponin-based Matrix-M™ adjuvant in a single formulation (COVID-NanoFlu Combination Vaccine).
In preclinical studies, the COVID-NanoFlu Combination Vaccine demonstrated robust, functional immune responses to each component of the quadrivalent influenza vaccine and the SARS-CoV-2 spike protein, with Matrix-M adjuvant playing a key role.
Furthermore, both NVX-CoV2373 and NanoFlu have demonstrated strong results as standalone vaccines in Phase 3 clinical trials.
"This study is the first-of-its-kind to evaluate the vaccine's potential to induce a robust immune response, augmented by our Matrix-M adjuvant, against two life-threatening diseases simultaneously," commented Gregory M. Glenn, M.D., President of Research and Development, Novavax, in a press release.
"The combination of these two vaccines, which have individually delivered outstanding results with favorable safety and tolerability profiles, may lead to greater efficiencies for the healthcare system and achieve high levels of protection against COVID-19 and influenza with a single regimen."
NVX-CoV2373 has also been evaluated in a co-administration study where it was administered simultaneously with an approved influenza vaccine from Seqirus, adjuvanted, trivalent seasonal influenza vaccine (aTIV). The study demonstrated that vaccine efficacy appeared to be preserved in those receiving both vaccines compared to those vaccinated with NVX-CoV2373 alone.
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.